Interventions for latent autoimmune diabetes (LADA) in adults

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Brophy, Sinead ^a   Brunt, H ^b   Davies, H ^b   Mannan, S ^b   Williams, R ^b  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

Autoimmune diseases *drug therapy; immunology ; C peptide blood ; Diabetes mellitus, type 1 *drug therapy; immunology ; Diabetes mellitus, type 2 *drug therapy; immunology ; Drugs, chinese herbal therapeutic use

Indexed keywords

ACARBOSE; AUTOANTIGEN; C PEPTIDE; GLIBENCLAMIDE; GLICLAZIDE; GLITAZONE DERIVATIVE; GLUCOSE; GLUTAMATE DECARBOXYLASE 65; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ABDOMINAL PAIN; ADULT; ANOREXIA; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DIARRHEA; DIET THERAPY; DRUG DOSE COMPARISON; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EDEMA; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE INFLAMMATION; INSULIN DEPENDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LACTIC ACIDOSIS; LATENT AUTOIMMUNE DIABETES; LEUKOCYTOSIS; LIFESTYLE MODIFICATION; LIVER TOXICITY; METABOLIC REGULATION; ORAL GLUCOSE TOLERANCE TEST; PILOT STUDY; RANDOMIZATION; REVIEW; SIDE EFFECT; TASTE DISORDER; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 44949210532     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006165.pub2     Document Type: Review

References (75)

1. Agardh 2005 {published data only} Agardh C-D, Cilio C, Lethagen A, Lynch K, Leslie D, Palmer M, et al.Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. Journal of diabetes and its complications 2005;19:238-46.
2. Cabrera-Rode 2002 {published data only} Cabrera-Rode E, Perich P, Diaz-Horta O, Tiberti C, Molina G, Arranz C, et al.Slowly progressing type 1 diabetes: Persistence of islet cell autoantibodies is related to glibenclamide treatment. Autoimmunity 2002;35(7):469-74.
3. Davis 2005 {published data only} Davis T, Wright A, Mehta Z, Cull C, Stratton I, Bottazzo G, et al.Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control [UKPDS 70]. Diabetologia 2005;48:695-702. [MEDLINE: 15729570].
4. Kobayashi 1996 {published data only} Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta cell failure in islet cell antibody positive patients with clinical features of NIDDM. Diabetes 1996;45:622-6.
5. L-Hallin 1999 {published data only} Landstedt-Hallin L, Arnert P, Lins PE, Bolindert J, Olsen H, Groop L and scandinavian insulin sulphonylurea study group research team. The role of sulphonylurea in combination therapy assessed in a trial of sulphonylurea withdrawal. Diabetes Medicine 1999;16:827-34.
6. Maruyama 2003 {published data only} Maruyama T, Shimada A, Kanatsuka A, Kasuga A, Takei I, Yokoyama J, et al.Multicenter prevention trial of slowly progessive type 1 diabetes with small dose of insulin (the Tokyo Study). Annals of the New York Academy of Sciences 2003;1005:362- 9.
7. Zhou 2005 {published data only} *Zhou Z, Li X, Huang G, Peng J, Yang L, Yan X, Wang J. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes [LADA]. Diabetes/metabolism research and reviews 2005;21:203-8.
8. Zhu 2004 {published data only} *Zhu L-Q, Liu Y-H, Huang M. Study on improvement of islet beta cell function in patients with latent autoimmune diabetes mellitus in adults by integrated Chinese and Western Medicine. Chinese journal of integrated traditional and Western Medicien 2004;24(7):581-4.
9. Alvarsson 2003 *Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, Fernqvist-Forbes E, Steen L, Westermark G, Westermark P, Orn T, Grill V. Beneficial effects of insulin versus sulphonylurea on insuin secretion and metabolic control in recently diagnosed type 2 diabetes patients. Diabetes Care 2003;26(8):2231-2237.
10. Bjork 1996 Bjork E, Berne C, Kampe O, Wibell L, Oskarsson P, Karlsson F. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 1996;45:1427-1430.
11. Chaillous 2000 Chaillous L, Lefevre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C, Bouhanick B, Mogenet A, Nicolino M, Carel J-C, Lecomte P, Marechaud R, Bougneres P, Charbonnel B, Sai P. Oral insulin administration and residual Beta cell function in recent onset type 1 diabetes: a multicentre randomised controlled trial. The Lancet 2000;356:545-549.
12. Conget 2005 Conget I, Aguilera E, Pellitero S, Naf S, Bendtzen K, Casamitjana R, Gomis R, Nicoletti F. Lack of effect of intermittently administered sodium fusidate in patients with newly diagnosed type 1 diabetes mellitus: the FUSIDM trial. Diabetologia 2005;48:1464-1468. [MEDLINE: 15995847].
13. DCCT Group 1998 DCCT Research Group. Effect of intensive therapy on residual beta cell function in patients with type 1 diabetes in the diabetes control and complications trial. Annals of Internal Medicine 1998;128(7):517-523.
14. E-Longmire 2004 Ergun-Longmire B, Marker J, Zeidler A, Rapaport R, Raskin P, Bode B, Schatz D, Vargas A, Rogers D, Schwartz S, Malone J, Krischer J, Maxlaren N. Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes. Ann. N.Y.Acad.Sci 2004;1029:260-277.
15. Goday 1993 Goday A, Pujol-Borrell R, Fernadez J, Casamitjana R, Rios M, Vilardell E, Gomis R. Effects of a short prednisone regime at clinical onset of type 1 diabetes. Diabetes Research and Clinical Practice 1993;20:39-46.
16. Heise 2005 Heise T, Bott S, Tusek C, Stephan J-A, Kawabata T, Finco-Kent D, Liu C, Krasner A. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin. Diabetes Care 2005;28:2161-2169. [MEDLINE: 16123484].
17. Karges 2004 Karges B, Durinovic-Bello, Heinze E, Boehm B, Debatin K-M, Karges W. Complete long term recorvery of beta cell function in autoimmune type 1 diabetes after insulin treatment. Diabetes Care 2004;27(5):1207-1208. [MEDLINE: 15111548].
18. Kobayashi 2002 Kobayashi T, Maruyama T, Shimada A, Kasuga A, Kanatsuka A, Takei I, Tanaka S, Yokoyama J. Insulin intervention to preserve beta cells in slowly progressive insulin dependent (type 1) diabetes mellitus. Ann N.Y. Acad Sci 2002;958:117-130.
19. Leslie 1996 Leslie R. Intervention in patients with type 1 diabetes masquerading as type II diabetes. Diab. Nutr. Metab 1996;9:319-324.
20. Linn 1996 Linn T, Ortac K, Laube H, Federlin K. Intensive therapy in adult insulin dependent diabetes mellitus is associated with improved insulin sensitivity and reserve: a randomized, controlled prospective study over 5 years in newly diagnosed patients. Metabolism 1996;45(12):1508- 1513.
21. Littorin 1999 Littorin B, Sundkvist G, Hagopian W, Landin-Olsson M, Lernmark A, Ostman J, Arnqvist H, Blohme G, Bolinder J, Eriksson J, Lithner F, Schersten B, Wibell L. Islet cell and glutamic acid decarboxylase antibodies present at diagnosis of diabetes predict the need for insulin treatment. Diabetes Care 1999;22(3):409-412.
22. Martin 1991 Martin S, Schernthaner G, Nerup J, Gries F, Koivisto V, Dupre J, Standl E, Hamet P, McArthur R, Tan M, Swason K, Mehta A, Vliet S, Von Graffenried B, Stiller C, Kolb H. Follow-up of cyclosporin A, treatment in type 1 (insulin - dependent) diabetes mellitus: lack of long term effects. Diabetologia 1991;34:429-434.
23. Matsumoto 2005 Matsumoto, M, Satou, S. Small doses of insulin may prevent the decrease of intrinsic insulin secretion in anti-GAD, ICA and IA-2 antibody-positive slowly progressive type 1 diabetes. [Japanese]. Journal of the Japan Diabetes Society 2005;48(4):257-261.
24. Mattews 1998 Matthews D, Cull C, Stratton I, Holman R, Turner R. UKPDS 26: Sulphonylurea failure in non-insulin dependent diabetic patients over six years. Diabetic medicine 1998;15:297-303.
25. Mayorov A 2005 Mayorov A, Naumenkova I, Antsiferov M, Dedov I. Influence of insulin treatment on insulin sensitivity in insulin requiring type 2 diabetes patinets. Diabetes Research and Clinical Practice 2005:S54-S59. [MEDLINE: 15955377].
26. Ovalle 2004 Karges B 2004.
27. Ovalle F, Bell D. Effect of Rosiglitazone versus insulin on the pancreatic beta cell function of subjects with type 2 diabetes. Diabetes Care 2004;27(11):2585-2589. [MEDLINE: 15504990].
28. Pozzilli 1997 Pozzilli P, Visalli N, Cavallo M, Signore A, Baroni M, Buzzetti R, Fioriti E, Mesturino C, Fiori R, Romiti A, Giovannini C, and the IMDIAB study Group. Vitamin E and nicotinamide have similar effects inmaintainig residual beta cell function in recent onset insulin dependent diabetes (the IMDIAB IV study). European Journal of Endocrinology 1997;137:234- 239.
29. Pozzilli 2000 Pozzilli P, Pitocco D, Visalli N, Cavallo G, Buzzetti R, Crino A, Spera S, Suraci C, Multari G, Cervoni M, Bitti M, Matteoli M, Marietti G, Ferrazzoli F, Cassone M, Giordano C, Sbriglia M, Sarugeri E, Ghirlanda G. No effect of oral insulin on residual beta-cell function in recent-onset type 1 diabetes (the IMDIAB VII). Diabetologia 2000;43:1000-1004.
30. Pugliese 2003 Pugliese A. Peptide-based treatment for autoimmune diseases: learning how to handle a double-edged sword. J Clin Invest 2003;111:1280-1282.
31. Ravnik-Oblak 1995 Ravnik-Oblak M, Mrevlje F. Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure. Diabetes Research and Clinical Practice 1995;30:27-35.
32. Sa 2003 Sa J, Silva R, Nasri F, Velloso L, Chacra A, Dib S. Non-obese adult onset diabetes with oral hypoglycemic agent failure: islet cell autoantibodies or reversible beta cell refractoriness?. Brazillian Journal of Medical and Biological Research 2003;36:1301-1309.
33. Schories 2004 Schories M, Peters T, Rasenack J, Reincke M. Islet-cell antiboides and type 1 diabetes after treatment with interferon-alpha. Dtsch Med Wochenschr 2004;129:1120-1124.
34. Scranton 2004 Scranton R, Su M, Turner R, Testa M. Quality of life considerations for insulin vrsus oral agent therapy in persons presenting with characteristics of latent autoimmune diabetes in adults [LADA]. American Diabetes Association. 2004:Abstract number: 1835-P.
35. Secchi 1990 Secchi A, Pastore M, Sergi A, Pontiroli A, Pozza G. Prednisone adminisstration in recent onset type 1 diabetes. Journal of autoimmunity 1990;3:593-600.
36. Steffes 2003 Steffes M, Jackson M, Sibley S, Thomas W. Beta cell Function and the development of diabetes related complicaitons in the diabetes control and complicaitons trial. Diabetes Care 2003;26(3):832-836.
37. Stenstrom 2005 Stenstrom G, Gottsater A, Bakhtadze E, Berger B, Sundkvist G. Latent autoimmune diabetes in adults: Definition, prevalence, Beta cell function and treatment. Diabetes 2005;54(S2):S68-S72.
38. Takino 1998 Takino H, Yamasaki H, Sera Y, Abe T, Ozaki M, Kondo H, Sakamaki H, Kawasaki E, Yamaguchi Y, Nagataki S, Eguchi K. The preliminary report from the nation-wide prevention study for type 1 diabetes initially diagnosed as type 2 in Japan. Diabetes Metab. Rev 1998;14:329-335.
39. Turner 1997 Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay I Shattock M, Bottazzo G, Holman R. UKPDS 25: autoantibodies in islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. The Lancet 1997;350:1288-1293.
40. Vidal 2000 Vidal J, Fernandez-Balsells M, Sesmilo G, Aguilera E, Casamitjana R, Gomis R, Conget I. Effects of Nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes. Diabetes Care 2000;23(3):360-364.
41. Zinman 2004 Zinman B, Kahn S, Haffner S, O'Neill M, Heise M, Freed M for the ADOPT study group. Phenotypic Characteristics of GAD antibody positive recently diagnosed patients with type 2 diabetes in north America and Europe. Diabetes 2004;53:3193-3200. [MEDLINE: 15561950].
42. Brophy 2007 Randomised, controlled, parallel-group study to investigate the clnical effictiveness of early insulin treatment in patients with LADA. Ongoing study 2007.
43. Buzzetti 2006 Non Insulin Requiring Autoimmune Diabetes (NIRAD) project. Ongoing study 2006.
44. Palmer 2000 Rosiglitazone intervention study on patients with type 1.5 diabetes. Ongoing study 2000.
45. Zhou 2005 (b) Zhou Z, Liao N, Li X, Lei M. Vitamin D supplementation in adults with latent autoimmune diabetes [LADA]. EASD 2005 Conference proceedings 2005.
46. Beales 2002 Beales P, Pozzilli P. Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes. Diabetes /Metabolism Research and Review 2002;18(2):114-7.
47. Bingley 2003 Bingley P, Bonifacio E, Mueller P. Diabetes Antibody Standardization Program, first assay proficiency evaluation. Diabetes 2003;52(5):1128-36.
48. Brophy 2006 Brophy S, Williams D.R.R, Leslie D on behalf of the Action LADA Research Group. Epidemiology of latent autoimmune diabetes [LADA] in eight centres in Europe. Diabetic medicine. 2006;Vol. 23:4 Suppl.
49. Cabrera-Rode 2002 Cabrera-Rode E, Perich P, Diaz-Horta O, Tiberti C, Molina G, Arranz D, et al.Slowly progressing type 1 diabetes: persistence of islet cell autoantibodies is related to glibenclamide treatment. Autoimmunity 2002;35(7):469-74.
50. Cohen 1960 Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37-46.
51. Gale 2005 Gale E. Latent autoimmune diabetes in adults: a guide for the perplexed. Diabetologia 2005;48:2195-9.
52. Higgins 2002 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine 2002;21:1539-58.
53. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327(7414):557- 60.
54. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
55. Kobayashi 1996 Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996;45(5):622-6.
56. Kobayashi 2002 Kobayashi T, Maruyama T, Shimada A, Kasuga A, Kanatsuka A, Takei I, et al. Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (type 1) diabetes mellitus. Annals of the New York Academy of Sciences 2002;958:117-30.
57. Lau 2006 Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333:597-600.
58. Leslie 2006 Leslie R.D, Williams D.R.R, Pozzelli P. Type 1 diabetes and latent autoimmune diabetes in adults (LADA): one end of the rainbow. The Journal of clinical endocrinology and metabolism 2006;91(5):1654-9.
59. Lewis 2001 Lewis S, Clarke M. Forest plots: trying to see the wood and the trees. BMJ 2001;322(7300):1479-80.
60. Lohmann T 2001 Lohmann T, Kellner K, Verlohren HJ, Krug J, Steindorf J, Scherbaum WA, et al.Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA). Diabetologia 2001;44(8):1005-10.
61. Maruyama 2003 Maruyama T, Shimada A, Kanatsuka A, Kasuga A, Takei I, Yokoyama J, et al.Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin (the Tokyo study): preliminary report. Annals of the New York Academy of Sciences 2003;1005:362-9.
62. Moher 1999 Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;354(9193):1896-900.
63. Nabhan 2005 Nabhan F, Emanuele M, Emanuele N, Nabhan F. Latent autoimmune diabetes of adulthood. Unique features that distinguish it from type 1 and 2. Postgraduate Medicine 2005;117(3):7-12.
64. Naik 2003 Naik R, Palmer J. Latent autoimmune diabetes in adults (LADA). Reviews in Endocrine and Metabolic Disorders 2003;4:233- 41.
65. Owen 2003 Owen KR, Stride A, Ellard S, Hattersley AT. Etiological investigation of diabetes in young adults presenting with apparent type 2 diabetes. Diabetes Care 2003;26(7):2088-93.
66. Palmer 2002 Palmer J. Beta cell rest and recovery - does it bring patients with latent autoimmune diabetes in adults to euglycemia?. Annals of the New York Academy of Sciences 2002;958:89-98.
67. Pozzilli 2001 Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization and potential prevention. Diabetes Care 2001;24(8):1460-7.
68. Schernthaner 2001 Schernthaner G, Hink S, Kopp H, Muzyka B, Streit G, Kroiss A. Progress in the characterization of slowly progressive autoimmune diabetes in adult patients (LADA or type 1.5 diabetes). Experimental Clinical Endocrinology Diabetes 2001;109:S94-S108.
69. Scranton R 2004 Scranton R, Su M, Turner R, Testa M. Quality of life considerations for insulin vrsus oral agent therapy in persons presenting with characteristics of latent autoimmune diabetes in adults [LADA]. American Diabetes Association. 2004:Abstract number: 1835-P.
70. Stenstrom 2005 Stenstrom G, Gottsater A, Bakhtadze E, Berger B, Sundkvist G. Section II: Type 1- related forms of diabetes. Latent autoimmune diabetes in adults. Diabetes 2005;54:S68-S72.
71. Sterne 2001 Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other biases. In: EggerM, Davey SmithG, AltmanDG editor(s). Systematic Reviews in Health Care; Meta-analysis in Context. London: BMJ Publishing Group, 2001:189-208.
72. Takino 1998 Takino H, Yamasaki H, Sera Y, Abe T, Ozaki M, Kondo H, et al.The preliminary report from the nation-wide prevention study for type 1 diabetes initially diagnosed as type 2 in Japan. Diabetes/metabolism reviews 1998;14(4):334-5.
73. Tuomi 1993 Tuomi T, Groop L, Zimmet P, Rowley M, Knowles W, MacKay I, et al.Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993;42:359-62.
74. Turner 1997 Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, et al.UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997;350(9087):1288-93.
75. Zhou 2004 Zhou Z, Li X, Huang G, Peng J, Yang L, Yan X, et al.Rosiglitazone combined with isulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA). Diabetes/ Metabolism Research and Review 2004;21(2):203-8.